The US Food and Drug Administration approved Shandong Xinhua Pharmaceutical's (SHE:000756) active pharmaceutical ingredient application for sevelamer carbonate, according to a Tuesday filing with the Shenzhen Stock Exchange.
The drug is used for hyperphosphatemia or high blood phosphate levels in adults undergoing dialysis, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.